These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 5170343)

  • 21. Thrombocythaemia and multiple myeloma. A report on two cases.
    Selroos O; van Assendelft A
    Acta Med Scand; 1977; 201(3):243-7. PubMed ID: 557871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multiple myeloma transforming into acute leukaemia (author's transl)].
    Mayans J; Redon J; Badia L; Herranz C; Calabuig JR; Sanz MA; Soler A; Caballero M; Marty ML
    Sangre (Barc); 1977; 22(6):1026-9. PubMed ID: 601670
    [No Abstract]   [Full Text] [Related]  

  • 23. [Multiple myeloma and acute leukemia. Simultaneous evolution of plasmacyte and myelomonocytic clones].
    Renoux M; Bernard JF; Bezeau A; Amar M; Boivin P
    Sem Hop; 1978 Sep 18-25; 54(25-28):809-13. PubMed ID: 214859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melphalan kinetics in hyperthermic isolation perfusion of the extremities.
    Loos U; Musch E; Rauschecker H; Willenbrock C
    J Chemother; 1989 Jul; 1(4 Suppl):1246-7. PubMed ID: 16312851
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210.
    Young RC; DeVita VT
    Cancer Res; 1970 Jun; 30(6):1789-94. PubMed ID: 5457940
    [No Abstract]   [Full Text] [Related]  

  • 26. [Myeloma and myelomonocytic leukemia. Role of melphalan. Ultrastructural and cytoenzymologic study].
    Marsan C; Henon P; Quillard A; Grimaldi A; Cywiner-Golenzer C; Adotti F; Dryll A; Roujeau J
    Pathol Eur; 1973; 8(4):287-98. PubMed ID: 4523953
    [No Abstract]   [Full Text] [Related]  

  • 27. Human myeloma: kinetics of the remission phase.
    Pileri A; Carmagnola A; Boccadoro M
    Acta Haematol; 1982; 68(3):237-40. PubMed ID: 6814152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of proliferative and clonogenic tumor cells in multiple myeloma.
    Karp JE; Burke PJ; Saylor PL; Humphrey RL
    Cancer Res; 1984 Sep; 44(9):4197-200. PubMed ID: 6744329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of the treatment of myeloma with a vincristine-melphalan combination].
    Roux H; d'Omezon Y; Gaborit P; Eisinger F; Serratrice G
    Rev Rhum Mal Osteoartic; 1979; 46(7-9):443-8. PubMed ID: 315613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognosis of multiple myeloma].
    Morell A; Skvaril F; Rüst HP; Spengler GA; Brunner K; Barandun S
    Schweiz Med Wochenschr; 1970 Nov; 100(46):1990-2. PubMed ID: 5507847
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of 1-phenylalanine mustard on anti-globulin antibodies in multiple myeloma.
    Waller M; Moon JH; Irby R; Toone EC
    Clin Exp Immunol; 1971 Jan; 8(1):91-100. PubMed ID: 4993198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
    Efferth T; Fabry U; Osieka R
    Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dhnmics of histological changes in the bone marrow in a patient with multiple myeloma during the process of treatment with sarcolysin].
    Voronin VM; Rybakova ME
    Probl Gematol Pereliv Krovi; 1969 Feb; 14(2):53-6. PubMed ID: 5351088
    [No Abstract]   [Full Text] [Related]  

  • 34. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proliferative activity, response to therapy and survival in multiple myeloma.
    Riccardi A; Montecucco C; Merlini G; Ucci G; Cremonini N; Gobbi PG; Ascari E
    Haematologica; 1984; 69(2):148-62. PubMed ID: 6429002
    [No Abstract]   [Full Text] [Related]  

  • 36. [Proliferative capacity of human leukemic bone marrow cells. Correlation between cytologic aspects, clinical evolution and therapeutic effectiveness].
    Faille A; Najean Y; Bernard J
    Nouv Presse Med; 1973 Apr; 2(14):889-94. PubMed ID: 4513312
    [No Abstract]   [Full Text] [Related]  

  • 37. The uptake, excretion, and radiation hazards of tritiated thymidine in humans.
    Straus MJ; Straus SE; Battiste L; Krezoski S
    Cancer Res; 1977 Feb; 37(2):610-8. PubMed ID: 832281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy.
    Alexanian R; Migliore PJ
    J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404
    [No Abstract]   [Full Text] [Related]  

  • 39. A new basis for treatment of multiple myeloma.
    Salmon SE; Durie BG; Hamburger AW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1568-72. PubMed ID: 694483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible significance of nonproliferating leukemic cells.
    Mauer AM; Saunders EF; Lampkin C
    Natl Cancer Inst Monogr; 1969 May; 30():63-79. PubMed ID: 5351830
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.